Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

BACKGROUND: Until today, adult and pediatric clinical trials investigating single-agent or combinatorial HDAC inhibitors including vorinostat in solid tumors have largely failed to demonstrate efficacy. These results may in part be explained by data from preclinical models showing significant activi...

Descripción completa

Detalles Bibliográficos
Autores principales: van Tilburg, Cornelis M., Milde, Till, Witt, Ruth, Ecker, Jonas, Hielscher, Thomas, Seitz, Angelika, Schenk, Jens-Peter, Buhl, Juliane L., Riehl, Dennis, Frühwald, Michael C., Pekrun, Arnulf, Rossig, Claudia, Wieland, Regina, Flotho, Christian, Kordes, Uwe, Gruhn, Bernd, Simon, Thorsten, Linderkamp, Christin, Sahm, Felix, Taylor, Lenka, Freitag, Angelika, Burhenne, Jürgen, Foerster, Kathrin I., Meid, Andreas D., Pfister, Stefan M., Karapanagiotou-Schenkel, Irini, Witt, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902473/
https://www.ncbi.nlm.nih.gov/pubmed/31823832
http://dx.doi.org/10.1186/s13148-019-0775-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902473/
https://www.ncbi.nlm.nih.gov/pubmed/31823832
http://dx.doi.org/10.1186/s13148-019-0775-1

Ejemplares similares